Article

European specialist shares perspectives on glaucoma surgery

When it comes to questions about the timing of glaucoma surgery and procedure choice, the general consensus in Europe is that early is better than late. According to guidelines from the European Glaucoma Society (EGS), nonpenetrating glaucoma surgery (NPGS) is a viable alternative to trabeculectomy, said Tarek Shaarawy, MD.

When it comes to questions about the timing of glaucoma surgery and procedure choice, the general consensus in Europe is that early is better than late. According to guidelines from the European Glaucoma Society (EGS), nonpenetrating glaucoma surgery (NPGS) is a viable alternative to trabeculectomy, said Tarek Shaarawy, MD.

Support for early surgical intervention finds its roots in pioneering work at Moorfields Eye Hospital, London, from glaucoma surgeons who showed that surgery was more effective than medical therapy in achieving visual field stability and IOP reduction, he said.

"These findings have since been corroborated by other multicenter studies," said Dr. Shaarawy, head, glaucoma sector, ophthalmology service, Department of Clinical Neurosciences, University of Geneva, Switzerland.

Discussing procedure choice, he noted that a more favorable safety profile is the primary reason why NPGS achieved a place alongside trabeculectomy in the EGS Terminology and Guidelines.

"Even leaders in glaucoma who [believe] trabeculectomy offers better IOP reduction accept that NPGS has a better safety margin and is deserving of a fair chance," Dr. Shaarawy said.

In contrast to trabeculectomy, NPGS is almost devoid of significant hypotony and is associated with a significantly lower incidence of cataract, he explained. Furthermore, after more than 25 years of experience with deep sclerectomy around the world, this nonpenetrating procedure has not been associated with a single published report of endophthalmitis, according to Dr. Shaarawy.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
© 2025 MJH Life Sciences

All rights reserved.